Postoperative Cyclic Oral Contraceptive Use for the Prevention of Endometrioma Recurrence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01092494|
Recruitment Status : Unknown
Verified March 2010 by Samsung Medical Center.
Recruitment status was: Not yet recruiting
First Posted : March 25, 2010
Last Update Posted : March 25, 2010
Ovarian endometriotic cyst (endometrioma) is one of the most common endometriotic lesions, and conservative laparoscopic surgery is the treatment of choice. However, the recurrence after surgery is common.
As repetitive surgery leads to morbidities and ovarian function decrease, recurrence after surgery frustrates both patients and clinicians. In this aspect, medical treatments have been offered after surgery to prevent or delay the recurrence. Gonadotropin-releasing hormone agonist (GnRHa) is frequently used in women with advanced endometriosis, but the efficacy is rather controversial. On the other hand, it has been demonstrated that oral contraceptives (OCs) could reduce or delay endometrioma recurrence, but data are still limited. Consequently, no one type of postoperative medical therapy has been shown to be superior in reducing the recurrence of endometrioma.
The rationale of postoperative medical therapy is that it could eradicate microscopic lesions which were not found and not treated sufficiently during surgery. Therefore, the maintenance of strongly suppressed condition induced by postoperative GnRHa treatment by addition of OCs could be a promising treatment to prevent the recurrence, but it has not been widely investigated.
We performed this retrospective cohort study to evaluate the efficacy of cyclic monophasic low-dose OCs as a maintenance therapy after GnRHa treatment for the suppression of endometrioma recurrence.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||232 participants|
|Official Title:||Efficacy of Postoperative Cyclic Oral Contraceptive Use After Gonadotropin-releasing Hormone Agonist for the Prevention of Endometrioma Recurrence|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||March 2010|
|Estimated Study Completion Date :||March 2010|
OC use after postoperative gonadotropin-releasing hormone agonist treatment
Only postoperative gonadotropin-releasing hormone agonist treatment
- recurrence rate of endometrioma [ Time Frame: 60 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092494
|Contact: DooSeok Choi, MD, PhDemail@example.com|
|Korea, Republic of|
|Samsung Medical Center||Not yet recruiting|
|Seoul, Korea, Republic of, 135-710|
|Contact: DooSeok Choi firstname.lastname@example.org|
|Study Director:||DooSeok Choi||Samsung Medical Center|